Stryker Corporation

SYK Healthcare Medical Devices

Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.

294.66 1.43 +0.49%
Market cap
$112.5B
P/E
30.3×
Fwd P/E
24.1×
Dividend yield
1.19%
F-score
5/9
Altman Z
4.81
Beneish M
−2.62
Dividend safety
82/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
16.51% 15.20% 15.08% 14.04%

+8 more TTM periods

Piotroski F-Score
7 7 5 4
ROA
7.91% 7.23% 7.15% 6.48%
ROIC
9.76% 8.97% 8.94% 6.54%
Return on Tangible Assets
31.89% 30.59% 29.95% 29.34%
Average Days of Receivables
52.88 51.58 58.70 54.54
Free Cash Flow per Share
12.26 11.94 11.21 11.08
Free Cash Flow
4,702.00 4,571.00 4,283.00 4,238.00
Capital Expenditures
(823.00) (804.00) (761.00) (594.00)
Other line items
Cash ROIC
11.09% 11.24% 10.11% 10.16%
Accounts Receivable Turnover
6.75 6.71 6.26 6.61
Accounts Payable Turnover
5.83 5.98 5.20 6.19
Inventory Turnover
1.67 1.74 1.80 1.65
Average Days of Payables
67.08 63.58 72.55 62.35
Days of Inventory on Hand
222.69 216.43 214.14 223.49
Tax Rate
(0.28) (0.27) (0.28) (0.12)
Research and Development Expense of Revenue
6.42% 6.45% 6.46% 6.48%
Selling, General and Administrative Expense of Revenue
33.99% 34.16% 34.44% 35.06%
Share Based Compensation of Revenue
0.97% 0.97% 0.97% 0.98%
Interest Coverage
7.29 6.61 7.86 —
Operating CF/Net income
1.48 1.61 1.55 1.64
Depreciation/Fixed assets
0.31 0.31 0.31 0.31
Capex/Depreciation
(0.67) (0.66) (0.64) (0.52)
Revenue per Share
67.37 66.00 65.71 63.76
Operating CF per Share
14.41 14.04 13.20 12.64
Capex per Share
(2.15) (2.10) (1.99) (1.55)
Capex to Sales
0.03 0.03 0.03 0.02

Fold the line items

Columns are period end dates